CLINICAL TRIALS PROFILE FOR UROLOGIC G IN PLASTIC CONTAINER
✉ Email this page to a colleague
505(b)(2) Clinical Trials for UROLOGIC G IN PLASTIC CONTAINER
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| OTC | NCT06819111 ↗ | Role of Medication in Making Urine Less Acidic as Part of Kidney Stone Prevention | NOT_YET_RECRUITING | University of Texas Southwestern Medical Center | PHASE1 | 2026-01-01 | Diet and medications are the cornerstones of kidney stone prevention. Potassium citrate is a commonly prescribed medication to help prevent kidney stones by making urine less acidic. There are different forms of potassium citrate such as over-the-counter tablet or powder, and slow-release tablets that require a prescription. However, it is unknown if one form is better than the others. Therefore, we want to compare different forms of potassium citrate and find out how well they work and whether patients prefer one form over the others. The study period will last approximately 6 weeks for each participant. Patients will be instructed to take one form of potassium citrate for one week at a time followed by a washout period for one week. This process will be completed a total of three times as we seek to study the effects of three forms of potassium citrate. At the end of each trial week patients will be asked to provide urine samples and complete two surveys. Urine will need to be collected for 24 hours, which will then be examined to determine the effects that each form of potassium citrate has on urine. In addition, completed surveys will give us information on how well the medication was tolerated and their satisfaction with the treatment. There is a possibility that patients like one form better than others, and it is also possible that they do not see a difference at all. Throughout the duration of the study patients will be asked to be a directed diet. This will be based on general recommendations by the National Kidney Foundation for the prevention of kidney stones. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for UROLOGIC G IN PLASTIC CONTAINER
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003930 ↗ | Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer | Completed | National Cancer Institute (NCI) | Phase 1/Phase 2 | 1999-09-01 | RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy and surgery may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus combination chemotherapy in treating patients who have stage II or stage III bladder cancer that can be removed by surgery. |
| NCT00003930 ↗ | Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer | Completed | Radiation Therapy Oncology Group | Phase 1/Phase 2 | 1999-09-01 | RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy and surgery may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus combination chemotherapy in treating patients who have stage II or stage III bladder cancer that can be removed by surgery. |
| NCT00132301 ↗ | Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma | Completed | Sanofi | Phase 3 | 2006-06-01 | VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical prostatectomy but who are at high risk for relapse. The standard of care is surveillance, with the addition of androgen deprivation at the time of biochemical relapse. This study will assess the effect of adding early chemotherapy to the standard of care on progression free survival in Veterans at high risk for progression after prostatectomy. |
| NCT00132301 ↗ | Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma | Completed | VA Office of Research and Development | Phase 3 | 2006-06-01 | VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical prostatectomy but who are at high risk for relapse. The standard of care is surveillance, with the addition of androgen deprivation at the time of biochemical relapse. This study will assess the effect of adding early chemotherapy to the standard of care on progression free survival in Veterans at high risk for progression after prostatectomy. |
| NCT00138008 ↗ | Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy | Completed | Ministry of Health, Labour and Welfare, Japan | Phase 3 | 2004-05-01 | The purpose of this study is to evaluate radiotherapy followed by endocrine therapy in comparison with endocrine therapy alone for PSA failure after radical prostatectomy. |
| NCT00138008 ↗ | Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy | Completed | Haruhiko Fukuda | Phase 3 | 2004-05-01 | The purpose of this study is to evaluate radiotherapy followed by endocrine therapy in comparison with endocrine therapy alone for PSA failure after radical prostatectomy. |
| NCT00148083 ↗ | Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia | Completed | Janssen, LP | Phase 3 | 2005-09-01 | The specific aim of this study is to determine whether the new, long-acting, form of risperidone, Risperdal Consta, improves the ability of schizophrenia patients to benefit from skills training. The hypothesis guiding this study is that Risperdal Consta, by improving verbal memory, will improve the ability to benefit from skills training interventions among schizophrenia patients. The primary objective of this study is to compare patients on Risperdal Consta to patients on other atypical antipsychotic medications in terms of their ability to benefit from skills training interventions. A secondary objective of this study is to determine whether patients taking Risperdal Consta improve in other areas of cognitive functioning and social functioning. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for UROLOGIC G IN PLASTIC CONTAINER
Condition Name
Clinical Trial Locations for UROLOGIC G IN PLASTIC CONTAINER
Trials by Country
Clinical Trial Progress for UROLOGIC G IN PLASTIC CONTAINER
Clinical Trial Phase
Clinical Trial Sponsors for UROLOGIC G IN PLASTIC CONTAINER
Sponsor Name
